EHA2021
Related
This book provides an overview of marginal zone lymphoma (MZL) for healthcare professionals and others with an interest in this blood cancer. It summarizes what is known about the pathophysiology of the disease, and discusses the importance of accurate diagnosis, staging, and prognosis, together with existing approaches to treatment and monitoring, including the latest evidence for new therapies in the relapsed/refractory (R/R) setting. With an eye to the future, it also reviews some of the therapies in development, which may ultimately improve quality of life and ensure better outcomes for patients with MZL.
Overview of current and future therapeutic options for the management of patients with B-cell lymphomas presented at ISHL13.
Overview of new approaches for the management of patients with lung cancer presented at ESMO 2024.
RATIONALE-305 (NCT03777657) is a randomized, double-blind, placebo-controlled, global Phase 3 trial comparing the efficacy and safety of tislelizumab combined with platinum and fluoropyrimidine chemotherapy to placebo combined with platinum and fluoropyrimidine chemotherapy as a first-line treatment for patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
This factsheet describes the final analysis of the Phase 3 RATIONALE-305 trial, where tislelizumab plus chemotherapy significantly improved overall survival (OS) in the intention-to-treat (ITT) population compared to chemotherapy alone. The safety profile of tislelizumab plus chemotherapy was manageable in patients with unresectable, locally advanced or metastatic GC/GEJC. No new safety signals were identified.
The RATIONALE-307, RATIONALE-304, and RATIONALE-303 trials were designed to evaluate the safety and efficacy of tislelizumab as a monotherapy and in combination with chemotherapy for the treatment of non-small cell lung cancer (NSCLC).
Download this factsheet to review the study design and key efficacy and safety takeaways.